Overview
The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).
Eligibility
Inclusion Criteria:
- History of relapsed and/or refractory multiple myeloma (RRMM) treated with at least 3 (Part 1) or at least 1 but not greater than 3 prior anti-myeloma treatment regimens (Part 2).
- Measurable multiple myeloma (MM) as per International Myeloma Working Group (IMWG).
- Eastern Cooperative Oncology Group performance status of 0-1.
Exclusion Criteria:
- Prior treatment with alnuctamab (Arm A), mezigdomide (Arm B), iberdomide (Arm C), elranatamab (Arm D) or BCMA-targeting therapy (Part 2 Arms A and D).
- Prior treatment with GPRC5D-targeting therapies.
- Other protocol-defined inclusion/exclusion criteria apply.
